Abstract
Herein we disclose SAR studies of a series of dimethylamino pyrrolidines which we recently reported as novel inhibitors of the PRC2 complex through disruption of EED/H3K27me3 binding. Modification of the indole and benzyl moieties of screening hit 1 provided analogs with substantially improved binding and cellular activities. This work culminated in the identification of compound 2, our nanomolar proof-of-concept (PoC) inhibitor which provided on-target tumor growth inhibition in a mouse xenograft model. X-ray crystal structures of several inhibitors bound in the EED active-site are also discussed.
Keywords:
Cancer; EED; PRC2; Protein-protein interaction inhibitor (PPI).
Copyright © 2017 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Cell Line, Tumor
-
Humans
-
Ligands
-
Mice
-
Microsomes, Liver / drug effects
-
Microsomes, Liver / metabolism
-
Polycomb Repressive Complex 2 / antagonists & inhibitors*
-
Polycomb Repressive Complex 2 / chemistry
-
Polycomb Repressive Complex 2 / metabolism*
-
Protein Binding
-
Pyrrolidines / chemical synthesis
-
Pyrrolidines / chemistry
-
Pyrrolidines / pharmacology*
-
Stereoisomerism
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry
-
Sulfonamides / pharmacology*
-
Xenograft Model Antitumor Assays
Substances
-
1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-4-(4-(4-(methanesulfonyl)piperazin-1-yl)phenyl)-N,N-dimethylpyrrolidin-3-amine
-
Antineoplastic Agents
-
EED protein, human
-
Ligands
-
Pyrrolidines
-
Sulfonamides
-
Polycomb Repressive Complex 2